XY Capital Ltd Acquires Shares of 33,970 Sanofi $SNY

XY Capital Ltd bought a new position in Sanofi (NASDAQ:SNY) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 33,970 shares of the company’s stock, valued at approximately $1,603,000. Sanofi comprises 0.8% of XY Capital Ltd’s holdings, making the stock its 26th largest holding.

Several other institutional investors also recently modified their holdings of SNY. Raymond James Financial Inc. lifted its holdings in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after acquiring an additional 2,635,867 shares during the period. Franklin Resources Inc. grew its stake in Sanofi by 9.9% in the 2nd quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after purchasing an additional 384,902 shares during the period. Mondrian Investment Partners LTD purchased a new stake in shares of Sanofi during the 3rd quarter valued at $171,742,000. Natixis Advisors LLC raised its stake in shares of Sanofi by 11.8% during the 3rd quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after purchasing an additional 327,569 shares during the period. Finally, Equity Investment Corp boosted its holdings in shares of Sanofi by 3.0% in the 3rd quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock worth $122,139,000 after buying an additional 75,255 shares during the last quarter. 14.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on SNY. Bank of America lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. HSBC restated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. Finally, TD Cowen reissued a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $62.67.

Sanofi Trading Down 0.1%

Shares of SNY stock opened at $43.60 on Friday. The company’s fifty day simple moving average is $46.85 and its two-hundred day simple moving average is $48.24. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. Sanofi has a 1 year low of $43.34 and a 1 year high of $59.17. The stock has a market capitalization of $106.34 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.13 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.